WebDisclosure WebDisclosure
Basculer en Français
9559 Companies
188835 Keywords
120583 Articles
100786 Press releases
Headlines Articles Press releases GEN İlaç Ve Sağlık Ürünleri A.Ş. Remove
  1. Home
  2. Companies
  3. GEN İlaç Ve Sağlık Ürünleri A.Ş.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 09/25/2024 at 15:05, 1 year 2 months ago

    GEN Reports Positive Phase 2 Trial Results for GN-037 Topical Cream

    Clinical Efficacy Phase 2 Trial Results GN-037 Topical Cream Plaque Psoriasis Treatment GEN Pharmaceuticals
  • BRIEF

    published on 09/25/2024 at 15:05, 1 year 2 months ago

    GEN annonce des résultats positifs de l'essai de phase 2 pour la crème topique GN-037

    Efficacité Clinique Résultats De L'essai De Phase 2 Crème Topique GN-037 Traitement Du Psoriasis En Plaques GEN Pharmaceutique
  • PRESS RELEASE

    published on 09/25/2024 at 15:00, 1 year 2 months ago

    GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

    GEN Pharmaceuticals announces positive Phase 2 trial results for GN-037 topical cream in treating plaque psoriasis, presented at EADV Congress 2024
    Phase 2 Trial GN-037 Topical Cream GEN Pharmaceuticals Plaque Psoriasis EADV Congress
    Logo of GEN İlaç Ve Sağlık Ürünleri A.Ş.
Accesswire
  • Published on 12/20/2025 at 00:30, 3 hours 35 minutes ago

    Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025

  • Published on 12/19/2025 at 22:00, 6 hours 5 minutes ago

    GMV Minerals Inc. Closes Non-Brokered Equity Financing

  • Published on 12/19/2025 at 18:30, 9 hours 35 minutes ago

    Eagle Plains Shareholders Approve all Matters at Annual General Meeting

  • Published on 12/19/2025 at 14:40, 13 hours 25 minutes ago

    Northern Superior Announces Closing of the Arrangement

  • Published on 12/19/2025 at 13:30, 14 hours 35 minutes ago

    Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE
EQS Group
  • Published on 12/19/2025 at 22:03, 6 hours 1 minute ago

    EAMD: Trading resumes on the Düsseldorf Stock Exchange, lawsuit filed by minority shareholders dismissed, capital increase for investments in drone projects in the defense tech sector

  • Published on 12/19/2025 at 21:40, 6 hours 24 minutes ago

    IMG Saxony-Anhalt: 2026 in Sight - Saxony-Anhalt Sets the Pace for Future Industries

  • Published on 12/19/2025 at 20:35, 7 hours 29 minutes ago

    Nobu Manchester breaks ground as Robert De Niro visits Manchester with Salboy

  • Published on 12/19/2025 at 20:15, 7 hours 49 minutes ago

    CSDS EU RNS Name Changes (19 December 2025)

  • Published on 12/19/2025 at 19:56, 8 hours 8 minutes ago

    Original-Research: European Lithium Limited (von First Berlin Equity Research GmbH): Buy

View all EQS
Les Echos
  • Published on 12/19/2025 at 21:57, 6 hours 7 minutes ago

    Mise à disposition du document d’enregistrement universel

  • Published on 12/19/2025 at 08:30, 19 hours 35 minutes ago

    Share capital decrease by way of treasury shares cancellation

  • Published on 12/19/2025 at 08:30, 19 hours 35 minutes ago

    Réduction du capital par voie d’annulation d’actions propres

  • Published on 12/19/2025 at 07:00, 21 hours 5 minutes ago

    EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS

  • Published on 12/19/2025 at 07:00, 21 hours 5 minutes ago

    EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2025 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy